NOX 8 Oct 2026, 8:15 AM

FDA feedback supports SOF-SKN Phase II plans

Noxopharm Ltd

Sign in to open PDF

No summary is available for this announcement — sign in to read the PDF in full.

Sign in for more about this company, including guidance changes and other insights.
Sign in